China's Connect Eyes Partnerships To Globalize Dermatitis Biologic
CEO Wants To Unlock Main Value Outside Home Market
Executive Summary
Watch out Sanofi. US- and China-based Connect BioPharma is looking to position its novel biologic for atopic dermatitis to compete head-on with best-selling Dupixent both inside and outside China in an increasingly crowded space, says co-founder and CEO Wei Zheng in an exclusive interview with Scrip.
You may also be interested in...
Arcutis’s Zoryve Succeeds In Second Phase III In Atopic Dermatitis
Immuno-dermatology specialist intends to submit the topical roflumilast to the US FDA during the first half of 2023, potentially adding an even larger indication to its approval for psoriasis.
Paradox Of China Biotech And What Lies Ahead In 2023
The hard going could get even tougher as a funding crunch continues for China’s biotech sector, which is being hit by a paradox that could see more pain ahead, leading investors to take the pulse of the sector as the Year of the Rabbit starts.
Cold Water On Already Frozen Sector: Industry Growing Wary Of China Price Cuts
From orphan to cancer drugs, more products have had their prices cut in the latest round of reimbursement negotiations in China. Although the 60% average across 100 medicines was considered mild given it didn’t go beyond the previous year, it was still chilling and is prompting more firms, both multinational and domestic, to walk away from the process.